secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2022-09-27T23:59:59+00:00
Accession:  0001193125-22-252180
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics appoints Noriyuki Kasahara to Board, promotes Fred Kamal to President and COO
--------------------------------------------------------------------------------

- Appointed Noriyuki Kasahara, M.D., Ph.D., to Board as Class I director and Chair of Science and Technology Committee.
- Promoted Fred Kamal, Ph.D., to President and COO; base salary increased to $475,000, annual target bonus 45%.
- Granted Kasahara option for 45,000 shares at $8.06; Kamal granted option for 15,000 shares at $8.06.
- Kasahara is Professor at UCSF with 30+ years in gene therapy, author of 150+ articles, inventor on 18 patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/d404270d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-252180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer